Scribe Therapeutics (SCTX) shares were up sharply in their Friday debut on Nasdaq after the company priced its initial public offering of 8.58 million shares at $15.00 per share.
The stock opened at $25 and was up over 50% at around $22.61 after midday.
The clinical-stage biotechnology company has upsized its IPO after pricing the shares at the high end of its indicative range.
It has granted its underwriters a 30-day option to purchase up to almost 1.3 million additional shares. Leerink Partners, Goldman Sachs, Guggenheim Securities and Wells Fargo Securities are joint book-running managers for the offering.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.